Mechanisms controlling the proliferative activity of neural stem and progenitor cells (NSPCs) have a pivotal role to ensure life-long neurogenesis in the mammalian brain 1 . How metabolic programs are coupled with NSPC activity remains unknown. Here we show that fatty acid synthase (Fasn), the key enzyme of de novo lipogenesis 2 , is highly active in adult NSPCs and that conditional deletion of Fasn in mouse NSPCs impairs adult neurogenesis. The rate of de novo lipid synthesis and subsequent proliferation of NSPCs is regulated by Spot14, a gene previously implicated in lipid metabolism [3] [4] [5] , that we found to be selectively expressed in low proliferating adult NSPCs. Spot14 reduces the availability of malonyl-CoA 6 , which is an essential substrate for Fasn to fuel lipogenesis. Thus, we identify here a functional coupling between the regulation of lipid metabolism and adult NSPC proliferation.
Adult neurogenesis, the generation of new neurons throughout adulthood in discrete brain regions, is critically involved in certain forms of cognition and has been associated with neuropsychiatric diseases such as depression and epilepsy 1, 7 . Recently, mechanisms regulating cell metabolism have been shown to control haematopoietic stem cell activity as well as proliferation of certain cancer cells [8] [9] [10] [11] . Whether regulation of cell metabolism governs cell proliferation in mammalian NSPCs remains unknown. Therefore, we here studied the role of de novo lipogenesis and its key enzyme Fasn 11, 12 in the context of adult NSPC biology.
Fasn messenger RNA and protein were expressed in the two main neurogenic areas of the adult brain, the subgranular zone (SGZ) of the dentate gyrus and the subventricular zone (SVZ) lining the lateral ventricles ( Fig. 1a and Supplementary Fig. 1a-h ). Fasn expression was high in proliferating NSPCs but downregulated in vitro after differentiation ( Supplementary Fig. 2a ). Proliferating NSPCs showed high levels of Fasn enzymatic activity relative to other dividing neural cells, such as non-myelinating Schwann cells, or to NSPCderived differentiated progeny ( Supplementary Fig. 2b, c) . High levels of Fasn activity were not due to impaired uptake of fatty acids, as NSPCs were competent to pick up free fatty acids in substantial amounts ( Supplementary Fig. 2d ). Mass-spectrometry-based metabolomics of dividing NSPCs, proliferating non-myelinating Schwann cells and differentiated progeny of NSPCs revealed striking differences in the metabolic profile of these discrete cell populations, confirming that NSPCs are in a distinct metabolic state (Fig. 1b) .
Pharmacological inhibition of Fasn activity using two independent inhibitors of Fasn (orlistat and cerulenin) reduced proliferation of rodent NSPCs in a dose-dependent manner ( Fig. 1c and Supplementary Fig. 3a , c, e) without inducing substantial amounts of cell death after short-term treatment ( Supplementary Fig. 3b, d ). In contrast, proliferation of non-myelinating Schwann cells was not affected by Fasn inhibition (Supplementary Fig. 3f ). However, prolonged inhibition of Fasn enhanced apoptotic cell death, suggesting that Fasn activity is also required for NSPC maintenance (Supplementary Fig. 3d ).
To genetically delete Fasn, we isolated NSPCs from mice carrying floxed alleles of the Fasn gene (Fasn flox/flox ) 12 . Retrovirus-based Crerecombinase-mediated excision of Fasn phenocopied the effects of pharmacological Fasn inhibition and reduced proliferation of NSPCs ( Fig. 1d and Supplementary Fig. 4a-c) .
We next conditionally deleted Fasn specifically in adult NSPCs in vivo by crossing Fasn flox/flox mice with mice harbouring tamoxifeninducible nestin-driven Cre recombinase and yellow fluorescent protein (YFP) reporter alleles in the ROSA locus (Fasn-cKO (conditional knockout)) 12, 13 . When analysed 40 days after the last tamoxifen injection, the number of recombined, YFP-expressing cells was dramatically reduced in both neurogenic areas in Fasn-cKO mice compared to their respective controls (Fig. 1e, f and Supplementary  Fig. 4d ). Phenotyping of YFP-labelled cells in the dentate gyrus revealed that the defects observed after conditional Fasn deletion manifested themselves early in the neurogenic lineage with a reduction in YFP-labelled cells occurring already at the stage of radial NSPCs and resulting in a dramatic loss of newly generated neurons (Fig. 1g, h and Supplementary Fig. 5a, b) . These results show that adult NSPCs require high levels of de novo lipogenesis for proper neurogenesis.
We next sought to identify genes that could regulate de novo lipogenesis in adult NSPCs and consequently alter proliferation of NSPCs. One gene that has previously been implicated as a context-dependent modulator of de novo lipogenesis is Spot14 (also known as thyroid hormone responsive protein (Thrsp)) [3] [4] [5] . In situ hybridization revealed that Spot14 mRNA expression was highly confined to the two neurogenic areas of the adult brain ( Fig. 2a and Supplementary Fig. 6a-c, e) . To study Spot14-expressing cells in more detail we used a bacterial artificial chromosome (BAC) transgenic mouse driving green fluorescent protein (GFP) under the control of the regulatory elements of the Spot14 gene (Spot14-GFP). In agreement with the mRNA expression, Spot14-GFP-expressing cells (hereafter called Spot14 1 cells) were largely restricted to the SGZ with only scattered expression outside the dentate gyrus, unlike previously described NSPC markers such as nestin, which also labels a substantial number of cells outside the adult neurogenic niches (Fig. 2a and Supplementary Fig. 6d, f) . Spot14 1 cells in the dentate gyrus showed a radial and non-radial cell morphology 14 , and co-labelled with NSPC markers such as Sox2 (92.7 6 15%), glial fibrillary acidic protein (Gfap; 85.3 6 4.2% in radial cells) and nestin (73.4 6 5.7% in radial cells) ( Fig. 2b and Supplementary Fig. 6g , h) 14 .
Of all Spot14
1 cells, only 9.36 6 1.1% were dividing. Non-radial Spot14 1 cells showed higher proliferation rates (7.86 6 1.0%) compared to radial Spot14 1 cells (1.7 6 0.5%), as measured by Ki67 colabelling ( Fig. 2b and Supplementary Fig. 6i ), indicating that the majority of Spot14 1 cells are not dividing under resting conditions.
Confirming the relative quiescence of Spot14 1 cells, we found that out of all Ki67 1 cells within the dentate gyrus, only 5.1 6 0.7% were positive for Spot14-GFP, whereas in the nestin-GFP mouse, 46.6 6 3.7% of all Ki67 1 cells were GFP positive ( Supplementary Fig. 6j ). To show directly that cells expressing Spot14 possess neurogenic stem-cell potential in the adult brain we generated a BAC transgenic mouse expressing tamoxifen-inducible Cre under the regulatory elements of the Spot14 gene (Spot14-CreER 
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injections (1 month and 3 months later) we found YFP labelling of new granule cells expressing doublecortin (Dcx) and the pan-neuronal marker NeuN (neuronal nuclei; also known as RNA binding protein Fox1 homologue 3) besides labelling of radial and non-radial NSPCs, both in the dentate gyrus and SVZ (Fig. 2c, d and Supplementary  Fig. 7b-d) . These findings indicate that Spot14-expressing cells constitute neurogenic NSPCs within the adult brain.
To further characterize Spot14 1 cells on functional and molecular levels, we prospectively isolated NSPCs from Spot14-GFP transgenic mice and used FACS to separate Spot14 1 and Spot14 2 NSPCs (Supplementary Fig. 8a, b) . Both Spot14 1 and Spot14 2 NSPCs expressed Sox2 and nestin (data not shown), self-renewed over an extended period of time in vitro and gave rise to neuronal and glial cells, indicating multipotency ( Supplementary Fig. 8c-e) . However, we observed reduced proliferation of Spot14 1 cells compared to Spot14 2 cells using monolayer cultures and clonal time-lapse imaging (Fig. 3a, b and Supplementary Videos 1-4) 15 , suggesting that the low proliferative activity of Spot14 1 cells within the dentate niche is maintained during culture conditions, a finding that was also supported by gene expression profiling ( Supplementary Fig. 9a, b and Supplementary Tables 1-6 ).
Given the low proliferation rate of Spot14 1 cells in vivo and in vitro we tested whether manipulation of Spot14 expression levels impacts NSPC proliferation. Retrovirus-mediated overexpression of Spot14 reduced proliferation of cultured NSPCs (Fig. 3c and Supplementary  Fig. 10a ). To test for a function of Spot14 in NSPC activity in vivo, we injected lentiviruses expressing short hairpin RNAs (shRNAs) and the fluorescent label mCherry into Spot14-GFP reporter mice. Knockdown of Spot14 mediated by shRNAs led to a shift in Spot14 1 cells towards non-radial, more-proliferative NSPCs, compared to control cells expressing non-targeting shRNAs (Fig. 3d and Supplementary  Fig. 10b ).
We next sought to identify a mechanism by which Spot14 controls NSPC proliferation. Spot14 has been shown to interact with Mig12 (Mid1-interacting protein 1), an activator of acetyl-coenzyme A (CoA)-carboxylase (Acc), the enzyme that catalyses the production of malonyl-CoA, which is a substrate for Fasn to generate new palmitate 16 ; however, heterodimerization with Spot14 impairs the ability of Mig12 to activate Acc, leading to decreased Acc activity 6 . We found expression of Fasn in Spot14 1 cells and high levels of Mig12 in adult NSPCs (Fig. 4a, b and Supplementary Fig. 11a-d) . In addition, Spot14 and Mig12 were both localized to the cytoplasm and coimmunoprecipitated ( Supplementary Fig. 11e, f) , suggesting that an interaction between Spot14 and Mig12 takes place in adult NSPCs. Retroviral overexpression of Mig12 rescued the Spot14-induced decrease in NSPC proliferation, indicating that a Spot14-Mig12 interaction is involved in the regulation of NSPC proliferation (Supplementary Fig. 11g ). Furthermore, virus-mediated knockdown of Mig12 reduced proliferation of NSPCs within the adult hippocampus in vivo and in vitro, as measured by EdU (5-ethynyl-29-deoxyuridine) pulse labelling ( Fig. 4c and Supplementary Fig. 11h, i) . Using targeted liquid chromatography tandem mass spectrometry we found that Spot14 overexpression led to a significant drop in malonyl-CoA levels without affecting expression levels of Fasn protein ( Fig. 4d and Supplementary Fig. 10c ), suggesting that Spot14 decreases malonylCoA levels and as a consequence lowers substrate availability for Fasn to fuel de novo lipogenesis. To directly assess levels of de novo lipogenesis upon Spot14 overexpression we measured total de novo lipid production by quantifying incorporation of radioactively labelled 14 Cacetate and 14 C-labelled glucose into lipids. We found that Spot14 overexpression significantly decreased levels of lipid synthesis (Fig. 4e) . These data support previous reports that Spot14 can act as a context-dependent modulator of de novo lipogenesis, either as an inhibitor 3 (as shown here for adult NSPCs) or activator of lipid synthesis 4, 5, 17 . In support of an essential role for Fasn and Spot14, we found that genetic deletion of Fasn or overexpression of Spot14 (both leading to reduced de novo lipogenesis) induced a shift in the metabolic profile of NSPCs, as determined by principal component analyses of Fig. 12 ). We next analysed the fate of newly synthesized lipids using thin-layer chromatography (TLC) and found that the majority of them (91.9%; Fig. 4g ) ended up in the membrane lipid-containing fractions, suggesting that NSPCs require a large part of new lipids for structural membranes.
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We identify here a novel mechanism governing adult neurogenesis by showing that adult NSPCs require Fasn-dependent lipogenesis for proliferation and that Spot14, a gene highly enriched in low proliferating NSPCs, downregulates NSPC proliferation by reducing lipid synthesis (Fig. 4g) . Thus, Spot14 seems to act as a molecular brake on Fasn-dependent lipogenesis, potentially also integrating other signals, such as thyroid hormone-regulated pathways, to ensure relative quiescence of adult NSPCs. However, future studies will have to further dissect and characterize the exact cellular mechanisms and NSPC-subtype during which high levels of lipogenesis are required for proper proliferation.
The targeting of metabolic pathways may hold potential for novel therapeutic approaches to treat diseases associated with failing adult neurogenesis, such as major depression or age-related cognitive decline.
METHODS SUMMARY
Mouse strains used were Spot14-GFP (Mutant Mouse Regional Resource Centres; MMRRC), nestin-GFP . The Spot14-CreER T2 BAC transgenic line was generated according to a published protocol 19 . All animal experiments were approved by the veterinary office of the Canton of Zurich, Switzerland. Cre-mediated recombination was induced by five consecutive intraperitoneal injections of tamoxifen (180 mg kg 21 ) at the age of 6 to 8 weeks. Retro-and lentiviral constructs, their production and stereotactic injections were carried out as described previously 20 . Brain tissue was sectioned and stained using methods published previously 20 . Murine NSPCs were cultured in DMEM with Ham's F12, supplemented with N2 supplement plus EGF, FGF and heparin. Fasn enzyme activity was determined using an assay described previously 12 .
Spot14
1 and Spot14 2 cells were live sorted and collected for RNA extraction, and gene expression analysis was then carried out using Affymetrix GeneChip arrays. To measure de novo lipid production in NSPCs overexpressing Spot14 and controls, cells were incubated with [1- H counts were measured. Metabolomics samples were analysed by ion pairing-reverse phase liquid chromatography tandem mass spectrometry on a Waters Acquity UHPLC coupled to a Thermo TSQ Quantum Ultra triple quadrupole instrument. Statistical analyses were carried out using two-tailed unpaired t-tests, non-parametric Mann-Whitney U-tests, the Kolmogorov-Smirnov test, or analysis of variance (ANOVA) followed by Fisher's post hoc test if appropriate. Significance levels were set at P , 0.05 (P , 0.01 for array analyses). A detailed methods section is available in the Supplementary Information. 
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